Generics BulletinAmgen and Samsung Bioepis look set to continue marketing their respective biosimilars to Alexion’s Soliris (eculizumab) in the UK, after the UK High Court of Justice’s Patents Court ruled that the fir
Pink SheetIndustry comments on two recent US Food and Drug Administration guidance documents on accelerated approval seek clear timelines for agency feedback on confirmatory study protocols and a better underst
In VivoLooking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav
ScripIt was Groundhog Day on 2 February. That week, any pharmaceutical groundhogs would have emerged from their burrows, glanced at the shadows of tariffs, a global trade war and weak Chinese demand and sc